Comparative Pharmacology
Head-to-head clinical analysis: AEROSPORIN versus ECONOCHLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSPORIN versus ECONOCHLOR.
AEROSPORIN vs ECONOCHLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polymyxin B binds to the lipid A portion of bacterial lipopolysaccharides, disrupting the outer membrane permeability and causing bacterial cell death. It is primarily active against Gram-negative bacteria.
Econazole nitrate inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
Polymyxin B sulfate: 1.5-2.5 mg/kg/day intravenously divided every 12 hours, or 25,000-30,000 units/kg/day intramuscularly divided every 12 hours. Ophthalmic: 1-2 drops in affected eye every 4 hours. Topical: Apply to affected area 3-4 times daily.
0.12 mg/kg IV bolus over 30 seconds, followed by continuous IV infusion at 0.12-0.6 mg/kg/h.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min), necessitating dose adjustment.
Terminal half-life: 8-10 hours in adults with normal renal function; prolonged to 15-20 hours in renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug via glomerular filtration. Approximately 60-70% of an intravenous dose is recovered in urine within 24 hours; minimal biliary/fecal elimination (<5%).
Renal: 80-90% as unchanged drug; fecal: <1%; biliary: minimal.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic